Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4.
Chow
K U
KU
Nowak
D
D
Hofmann
W
W
Schneider
B
B
Hofmann
W-K
WK
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D066298:In Vitro Techniques; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000503:physiopathology; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D001549:Benzamides; D047908:Intracellular Signaling Peptides and Proteins; D010879:Piperazines; D011743:Pyrimidines; C101296:prostate apoptosis response-4 protein; D000068877:Imatinib Mesylate